Press "Enter" to skip to content

Boston Based Alexion Pharmaceuticals Shares Performs Better

Alexion Pharmaceuticals Inc. shares inched 0.77% higher to $184.14 Monday. This proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.23% to 4,290.61 and the Dow Jones Industrial Average DJIA falling 0.44% to 34,283.27.Alexion Pharmaceuticals Inc. hit a new 52-week high, surpassing its previous peak of $183.05, which the company reached on June 16th. The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Gilead Sciences Inc. GILD fell 0.27% to $67.70, Vertex Pharmaceuticals Inc. VRTX rose 1.79% to $197.82, and Regeneron Pharmaceuticals Inc. REGN fell 1.43% to $542.70.

Alexion Pharmaceuticals Inc trading volume (1.1 M) remained 844,903 below its 50-day average volume of 2.0 M.This was the stock’s fourth consecutive day of gains. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines.

Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD).Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent.

In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *